|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 278, Issue 20, 18199-18206, May 16, 2003
From the Division of Molecular, Cellular, and Microbial Biology,
Department of Biological Sciences, University of Calgary, Calgary,
Alberta T2N 1N4, Canada and To develop a fast-acting clot dissolving agent, a
clot-targeting domain derived from the Kringle-1 domain in human
plasminogen was fused to the C-terminal end of staphylokinase with a
linker sequence in between. Production of this fusion protein in
Bacillus subtilis and Pichia pastoris was
examined. The Kringle domain in the fusion protein produced from
B. subtilis was improperly folded because of its
complicated disulfide-bond profile, whereas the staphylokinase domain
produced from P. pastoris was only partially active because
of an N-linked glycosylation. A change of the glycosylation residue, Thr-30, to alanine resulted in a non-glycosylated biologically active fusion. The resulting mutein, designated SAKM3-L-K1, was overproduced in P. pastoris. Each domain in SAKM3-L-K1 was
functional, and this fusion showed fibrin binding ability by binding
directly to plasmin-digested clots. In vitro fibrin clot
lysis in a static environment and plasma clot lysis in a flow-cell
system demonstrated that the engineered fusion outperformed the
non-fused staphylokinase. The time required for 50% clot lysis was
reduced by 20 to 500% under different conditions. Faster clot lysis
can potentially reduce the degree of damage to occluded heart tissues.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc. This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||